Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Tumor Activity Equipment Supplied In Europe
19 equipment items found
by:Genmab A/S based inCopenhagen V, DENMARK
In preclinical models of hematological malignancies, HexaBody®-CD38 demonstrated enhanced complement-dependent cytotoxicity and potent anti-tumor ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the expression of abnormally expressed genes in cancer. The compound has demonstrated a wide therapeutic window, with activity seen at a 48 mg ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to ...
Manufactured by:ITM Isotope Technologies Munich SE based inGarching / Munich, GERMANY
Ready-to-use Radiopharmaceutical for Diagnosis & Staging of Neuroendocrine Tumors (NETs) ...
Manufactured by:Santa Cruz Biotechnology, Inc. based inDallas, TEXAS (USA)
Pheophorbide a is a chlorophyll-related compound studied for its anti-tumor and anti-cancer ...
Manufactured by:BK Medical Holding Company, Inc. based inBurlington, MASSACHUSETTS (USA)
Fusing powerful real-time ultrasound images with pre-exam MRI data gives you better guidance to help accurately target lesions detected on the MRI images, potentially reducing the risk of missing high-grade tumors or under-staging tumors for active ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Alomfilimab SAR445256 (formerly KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Alomfilimab is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
by:Abivax based inParis, FRANCE
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto partnered with the Swiss Group for Clinical Cancer Research (SAKK) with the aim of conducting the first clinical study on the treatment of ...
Manufactured by:NeraCare GmbH based inFrankfurt, GERMANY
Melanoma is a serious form of skin cancer that begins in cells known as melanocytes. While it is less common than basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), melanoma is far more dangerous because of its ability to spread to other organs more rapidly if it not treated at an early ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
XPO1 has been shown to regulate nuclear export of many of the major tumor suppressor proteins and oncogenic cell growth regulators. Overexpression of XPO1 has been reported in many cancer types and is associated with aggressive tumor behavior and poor patient prognosis. Inhibition of XPO1 has been shown to restore tumor suppressor function and ...
Manufactured by:Scancell based inOxford, UNITED KINGDOM
Modi-1 is the first vaccine based on Scancell’s Moditope® platform. The vaccine is composed of a combination of three peptides from two target antigens that are commonly modified in cancer cells. The first is the cytoskeletal protein, vimentin, which is preferentially digested during autophagy. All mesenchymal tumours such as endometrial, renal, sarcomas, lymphomas and lung tumours ...
by:Pure Biologics SA based inWroclaw, POLAND
Triple-negative breast cancer (TNBC) is a highly proliferative, rapidly growing, and aggressive form of cancer. TNBC can be further categorized into three types: Type 1 (also known as the “cold” type) is characterized by a tumor with low infiltration of immune cells into the tumor microenvironment; Type 2 is characterized by inactive cells of the innate immune system; Type 3 (also ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
TG4001 is an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 ...
Manufactured by:Ascelia Pharma AB based inMalmö, SWEDEN
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...